Updated: Early sales of Lilly’s obesity pill appear to trail Novo’s
About 20,000 people are taking Eli Lilly’s obesity pill Foundayo after its first 20 days on the market, according to the company’s CEO David Ricks. This points to a markedly slower launch of the drug ...
April 30, 2026 07:19 AM EDTUpdated 07:38 AM Pharma Lack of specifics on obesity pill sales hover over Lilly’s first quarter Elizabeth Cairns Senior biopharma journalist Investors hoping for more accurate sales figures for Foundayo, Eli Lilly’s newly launched obesity pill, were disappointed Thursday when the company did not reveal them … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that